Exdensur (depemokimab) is the first and only ultra-long-acting biologic in the EU to treat severe asthma and chronic rhinosinusitis with nasal polyps
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.